A first-of-its-kind osteoporosis drug lowers the risk of bone fractures as well as or better than current medicines, studies in older women and men with prostate cancer suggest. Wall Street sees Amgen Inc.'s genetically engineered denosumab as a potential blockbuster crucial to the company's future. But given the crowded market of treatments for the bone-thinning disease, doctors see its expected high cost as a big drawback.
"It'll find a particular niche where it'll be used, but I don't see it as taking over the market," said Dr. Sundeep Khosla, a professor and osteoporosis researcher at the Mayo Clinic not involved in the studies ,The Associated Press reports.
Overall, those fractures appeared in 2.3 percent of the denosumab group, compared with 7.2 percent of patients taking placebo, according to Dr. Steven Cummings of California Pacific Medical Center in San Francisco and colleagues , ABC News reports.
However, d enosumab patients in the osteoporosis safety group had a slightly increased incidence of breast, pancreatic, gastrointestinal and reproductive cancers. ,Forbes reports.
Russian Finance Minister Anton Siluanov announced a possible move that Russia can take in response to new US sanctions
Not that long ago, American soldiers would train their skills to counter insurgent and partisan military organizations. These days, they are trained to show resistance to the regular army of a potential adversary
The Central Bank of Turkey announced measures to protect the financial market of Turkey against the background of the collapse of the Turkish lira and conflict of interests with the United States of America